Literature DB >> 14516418

Hydrochlorothiazide abolishes the anti-atherosclerotic effect of quinapril.

F A H Fonseca1, S S M Ihara, M C O Izar, E P Silva, N Kasinski, I E L Lopes, L E S A Pinto, T B Paiva, S Tufik, A A V de Paola, A C C Carvalho.   

Abstract

1. Antihypertensive treatment has been demonstrated to result in persistent reductions in morbidity and mortality due to stroke. However, the coronary risk attributable to hypertension has been only partially reversed. We hypothesized that diuretics could have unfavourable effects on atherosclerosis. 2. New Zealand rabbits were fed a 0.5% cholesterol-enriched diet for 12 weeks, followed by a 0.1% cholesterol diet for another 12 weeks. During the last 12 week period, 40 animals were randomly assigned to one of four groups: (i) group I was the control group; (ii) group II received hydrochlorothiazide (10 mg/day); (iii) group III received quinapril (30 mg/day); and (iv) group IV was treated with hydrochlorothiazide (10 mg/day) plus quinapril (30 mg/day). 3. The treatments did not affect either the lipid profile or serum electrolytes and oxidative stress. However, endothelium-dependent vasorelaxation in isolated aortic rings was significantly improved with quinapril (group III) treatment (P < 0.001 vs other groups). In addition, therapy with quinapril promoted a significant reduction in atherosclerosis (intima area, intima/media ratio and perimeter of vessel with plaque; P < 0.05 vs other groups), as well as in cholesterol content of the aorta (P < 0.05 vs groups II and IV). 4. In conclusion, hydrochlorothiazide did not modify atherosclerosis and, when added to quinapril treatment, impaired the anti-atherosclerotic effect seen with quinapril alone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14516418     DOI: 10.1046/j.1440-1681.2003.03911.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  3 in total

Review 1.  Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia.

Authors:  Sirirat Reungjui; Thongchai Pratipanawatr; Richard J Johnson; Takahiko Nakagawa
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-09       Impact factor: 2.894

2.  Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.

Authors:  Ulrich Kintscher; Peter Bramlage; W Dieter Paar; Martin Thoenes; Thomas Unger
Journal:  Cardiovasc Diabetol       Date:  2007-04-03       Impact factor: 9.951

3.  Circulating microparticles and central blood pressure according to antihypertensive strategy.

Authors:  Nayara D Massunaga; Carolina N França; Henrique T Bianco; Carlos E S Ferreira; Juliana T Kato; Rui M S Póvoa; Antonio M Figueiredo Neto; Maria Cristina O Izar; Francisco Antonio Helfenstein Fonseca
Journal:  Clinics (Sao Paulo)       Date:  2019-11-11       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.